DNMT3L is a catalytically inactive regulatory protein that plays essential roles in DNA methylation by activating DNMT3A and DNMT3B methyltransferases. The protein functions by binding to the catalytic domains of DNMT3A and DNMT3B, accelerating their binding to DNA and S-adenosyl-L-methionine, then dissociating after DNA binding occurs 1. DNMT3L recognizes unmethylated histone H3 lysine 4 and induces de novo DNA methylation through recruitment or activation of DNMT3 enzymes. In placental development, DNMT3L is necessary for establishing partially methylated domains (PMDs), a conserved mammalian epigenetic feature, as demonstrated by restoration of placental PMDs when DNMT3L is ectopically expressed in human trophoblast stem cells 2. The protein shows tissue-specific expression patterns and clinical significance in multiple contexts. DNMT3L is specifically expressed in testicular germ cell tumors, particularly embryonal carcinoma cells, where it serves as a novel diagnostic marker and is essential for tumor cell growth 3. Additionally, DNMT3L has been identified as a potential therapeutic target, with engineered CHARM systems using DNMT3L fusions successfully silencing pathogenic proteins like prion protein in mouse brains 4. Recent genetic studies have also implicated DNMT3L variants in Alzheimer's disease and related dementia risk 5.